30 results about "Cancer stem cell" patented technology

The present invention provides a compound with which a molecular probe capable of distinguishing NSCs from CSCs can be produced, and a method for detecting cancer stem cells using the compound. The present invention relates to a compound having a formyl group, a substrate moiety, a quenching moiety, and a luminescent moiety that is non-luminous due to the quenching moiety, wherein the luminescent moiety may be rendered luminous by detaching the substrate moiety by a substrate-degrading enzyme and also converting the formyl group to a carboxy group by an aldehyde dehydrogenase to allow the quenching moiety to dissociate.

Disclosed are 1,2,4,5-tetraoxane compounds and derivatives thereof having anticancer properties. Disclosed are pharmaceutical compositions and pharmaceutical formulations in unit dosage form suitable for delivering the compounds to a subject in need thereof. In addition to the compounds, the pharmaceutical compositions or formulations can include one or more active agents, such as one or more additional anticancer agents. Also disclosed are methods of treating, mitigating, or treating or ameliorating one or more symptoms associated with cancer in a subject. The methods include (i) administering to a subject in need thereof an effective amount of a compound. The compound can be administered by oral administration, parenteral administration, inhalation, mucosal administration, or a combination thereof. The compound can selectively kill cancer cells and / or cancer stem cells, but not non-cancer cells, by inducing ferroptosis in the cancer cells and / or cancer stem cells.

This invention provides a method for diagnosing or treating cancerous diseases that contains cancer stem cells. [Solution] A method for measuring cancer stem cells is provided, comprising detecting cells expressing CLDN6. In particular, the present invention provides a method for measuring cancer stem cells, comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method for treating or preventing cancer, comprising inhibiting and / or eliminating cancer stem cells by administering an antibody having the ability to bind to CLDN6 to a cancer patient.

Provided are methods relating to SIRPgamma as a biomarker for cancer cells, and in particular of cancer stem cells and lung adenocarcinoma. Disclosed are also methods of treatment, which involve administering a SIRPgamma targeted agent to a subject with cancer, alone or with another cancer therapy. Methods for diagnosing cancer, identifying subjects with high SIRPgamma levels for treatment, and monitoring SIRPgamma expressing tumors are also provided.

The present invention relates to a composition for the prevention or treatment of cisplatin-resistant cancer comprising an inhibitor of DUSP23 expression or activity as an active ingredient. It was found that DUSP23 expression is upregulated in cell clusters exhibiting characteristics of cancer stem cells, and that knocking down DUSP23 significantly reduces cell cluster formation as well as decreases the expression of SOX2, a major stem cell marker. Furthermore, DUSP23 expression was increased in lung cancer cells that had developed cisplatin resistance, and it was confirmed that the downregulation of DUSP23 inhibits self-renewal and invasive capabilities during the induction of cancer cell death. In addition, it was confirmed that DUSP23 plays an important role in promoting cancer stem cell characteristics through SOX2 expression. In conclusion, it has been shown that targeting DUSP23 can be a promising therapeutic strategy to overcome anticancer drug resistance in lung cancer, and the composition of the present invention is expected to be usefully utilized as a treatment for lung cancer cells with cisplatin resistance.

The present disclosure relates to compositions and methods for reducing cancer stem cells. In some aspects, the compositions and methods can comprise at least one metabolism modulating agent. In other aspects, the compositions and methods can comprise at least two metabolism modulating agents.

Provided herein are methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the activity of ZSCAN4 in cancer cells in the subject, thereby treating the cancer.

An object of the present invention is to provide a drug that suppresses the proliferation of cancer stem cells. Accordingly, it is an object to provide a composition and a method that can treat cancer, suppress cancer recurrence and suppress cancer metastasis. The above objects are achieved by a composition for suppressing proliferation of cancer stem cells comprising a triazolohalopyrimidine compound represented by the following general formula (I) as an active ingredient:

The present invention relates to a composition for inhibiting the growth of cancer stem cells and a use thereof. When treated with the EMP3 inhibitor, cancer stem cells expressing ALDH1 decrease in self-renewal potential, invasiveness, and migration ability and thus are restrained from growing, whereby cancer having stemness properties, which are resistant to conventional anticancer therapies, can be effectively treated.

Provided herein are compositions and methods for detecting presence of cancer cells, and treating the cancer cells, in a human, the method comprising: obtaining, or having obtained, a human tissue sample with cancer cells; and detecting in the human tissue sample for abnormalities in ribosome-associated quality control by detecting the presence of mitochondrial stress-induced protein carboxyl-terminal terminal alanine and threonine tailing (msiCAT-tailing) proteins, wherein the presence of msiCAT-tailing is indicative of the presence of cancer stem cells.

Compositions, methods, and uses of recombinant IL-8 antibodies, fragments thereof, or single-chain variable fragments (scFv) thereof with high affinity for IL-8 for targeting tumor-expressed or endogenous IL-8 are presented. Preferably, the recombinant IL-8 antibody or scFv fragment comprises a VFV comprising a first amino acid sequence selected from the group consisting of SEQ ID NOs: 1-15, 31-32. H segment, and / or a second amino acid sequence selected from the group consisting of SEQ ID NOs: 16-30, 33-34 L The recombinant IL-8 antibody or scFv fragment can be formulated as a pharmaceutical composition for administration to tumor-bearing patients to reduce tumor metastasis, reduce immunosuppression in the tumor microenvironment, or reduce a Th2-mediated immune response.

Disclosed are compounds, nanoparticles, and compositions for effective delivery of metabolic inhibitors to disease state cells. Also disclosed are methods of treating a subject in need thereof, such as a subject with cancer.

The present invention provides methods and kits a) for preventing and / or treating neuroblastoma (e.g., high-risk neuroblastoma) that is linked, in part, to high levels of ODC activity and increased cellular polyamine content, b) for predicting cancer patient survival, especially cancer patients whose cancer is linked, in part, to high levels of ODC activity and increased cellular polyamine contents, and c) for selecting treatment options for such patients based on the allelic nucleotide sequence or SNP at positions +263 and / or +316 of the ODC1 gene. The invention also provides, cancer treatment methods comprising the determination of the ODC1 genotype at the +263 and / or +316 positions, as a means to guide treatment selection, which includes, in some aspects the administration of pharmaceutically effective amounts of α-difluoromethylornithine (DFMO), either as a monotherapy or in combination with one or more other drugs. In addition, the present invention provides methods for preventing and / or treating patients that have been determined to have cancer stem cells, such as patients in cancer remission that are at risk for relapse.

Disclosed herein are compositions and methods related to a plurality of stem cells administered a TGF-beta pathway inhibitor and / or a Hippo pathway inhibitor. In some embodiments, the composition does not comprise a gel matrix and / or either mesenchymal stem cells or cancer stem cells. In some embodiments, at least 25% of the cells in the composition are dissociated. In some embodiments, the stem cells are agitated in the composition.

The present invention relates to a composition for inhibiting the growth of cancer stem cells, and a use thereof. A WDR34 inhibitor of the present invention inhibits the conversion of cancer cells into cancer stem cells and exhibits activity of inhibiting self-renewal, invasion, and migration of cancer stem cells, and thus can be effectively used as a cancer cell growth or metastasis inhibitor or a cancer stem cell growth inhibitor.

The present application relates to methods and uses of conjugates comprising antitumor agents (e.g., chemotherapeutic agents) conjugated to peptide compounds targeting Sortilin-expressing cancer stem cells (CSCs), in embodiments for the treatment of poor prognosis cancers refractory to standard antitumor therapies associated the presence of Sortilin-expressing CSCs, and for preventing or treating cancer relapse or recurrence.

The present invention relates to cancer cell-specific antibodies and uses thereof. According to one aspect, antibodies specific for membrane proteins of cancer stem cells or cancer cells exhibit a strong affinity for ITGA3 or VLA3 and excellent cellular internalization, therefore, the present invention can be effectively used in the diagnosis, treatment or research on the development of therapeutic agents for various cancers in the form of unconjugated antibodies, antibody-drug conjugates (ADCs), and other antibody complexes based on the antibodies.

Disclosed are compounds, methods, compositions, uses, and kits that allow for treating cancer. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Disclosed are compounds, methods, compositions, uses, and kits that may be used in regenerative medicine. The compounds utilized in the disclosure are of Formula (0) and (I).

An object of the present invention is to develop a technique of reducing cancer stem cells. The solution is to provide a human-derived anti-human Cripto-1 antibody containing specific amino acid sequences.

Compositions and methods for reducing cancer stem cells and / or treating cancer are provided. In some aspects, the compositions and methods can comprise at least one metabolism modulating agent. In other aspects, the compositions and methods can comprise at least two metabolism modulating agents.

The disclosed invention is generally in the field of synthetic small molecules and their use as drug, in particular in the treatment of cancer. Also provided is a method of inhibiting cancer stem cells. Also provided is a method for treatment of cancers and other diseases by affecting mitochondrial functions. Also provided is a method of making and using of the compounds.

Methods of isolating normal stem cells in culture derived from embryonic epithelial tissue and cancer stem cells derived from epithelial cancers and culture medium systems useful for epigenetically stable growth SOLUTION: A method for isolating stem cells from epithelial tissue, preferably columnar epithelial tissue, comprising: (I) culturing dissociated epithelial cells from a columnar epithelial tissue sample to form a stem cell colony; (ii) isolating single stem cells from the cell colony; and (iii) individually culturing the isolated single stem cells from step (ii) to form a culture of purified stem cell clones, wherein: Wherein each of the stem cell clones represents a clonal expansion of epithelial stem cells present in the columnar epithelial tissue sample, thereby isolating epithelial stem cells.SELECTED DRAWING: None

Provided herein, among other things, is a method for identifying a cancer patient that is at high risk for cancer recurrence. In some embodiments, the method may comprise analyzing a section of a tumor obtained from the cancer patient to quantify interactions between cancer stem cells and PDL1+ macrophages. In these embodiments, a higher level of interactions between cancer stem cells and PDL1+ macrophages in the tumor indicates that the patient is at high risk for cancer recurrence. In some embodiments, the method may comprise identifying the patient has having a high risk of cancer recurrence based on the results of this analysis and administering an adjuvant therapy to the patient.

Disclosed herein are macrolide compounds having senolytic activity. These compounds selectively target senescent cells, and may be used to reduce or eradicate senescent cells in a subject, and / or delay the onset of aging. These compounds also inhibit propagation of cancer stem cells, and may be used to treat cancer, and in particular inhibit the propagation of cancer stem cells responsible for metastasis and tumor recurrence. Formulae (I) & (II):

Methods of treating cancer, including methods that administer to a patient an agent that may be an inducer of cancer stem cell differentiation and mesenchymal to epithelial transition (MET) in multiple tumor cell lines in a 3D culture model that recapitulates clinically relevant tumor cell states in vitro. The differentiating activity of the agents in cancer stem cells may occur through over-activation, rather than inhibition, of the Notch pathway. Methods of screening agents, and pharmaceutical compositions.

Compounds and pharmaceutical compositions comprising compounds that inhibit ENL / AF9 YEATS and FLT3 are disclosed herein. Methods for suppressing oncogene expression in a cell, or for treating acute leukemias, using the compounds and pharmaceutical compositions comprising the compounds are also disclosed. The compounds, pharmaceutical compositions and methods can be used to inhibit key drivers of cancer and cancer stem cell survival.

Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O′), and (I):

Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O′), and (I):

The disclosure relates generally to a system, device, and method for cell culturing. In certain embodiments, the system, device, and method may be used to encapsulate single cells in embryo-like, core-shell microcapsules. In some embodiments, microfluidic devices may be utilized to fabricate core-shell hydrogel microcapsules, which may be used to encapsulate individual cells. In some embodiments, the disclosed system and method are utilized to encapsulate cancer stem cells. The disclosed system, device, and method can be used to isolate and culture CSCs, to facilitate the understanding of cancer biology and etiology, and to advance the development of effective CSC-targeted cancer therapies.

Described are methods for treating cancers overexpressing hyperpolarization activated cyclic nucleotide-gated channel (HCN) isoforms HCN1, HCN2, HCN3, and / or HCN4. The cancers are treated by administering to a subject in need of treatment an effective amount of an HCN inhibitor. The HCN inhibitor can be an inhibitor of HCN1, HCN2, HCN3, or HCN4, or an inhibitor that inhibits any combination of HCN1, HCN2, HCN3, and HCN4. The described methods are useful for reducing tumor size, putting cancer in remission, and reducing or stopping proliferation of cancer stem cells.